According to Dov, the reorganization is designed to maximize the value of the biopharmaceutical company’s existing pipeline and explore and pursue what it describes as “attractive financing opportunities.”
Reflecting their increased responsibilities in the company’s management in the wake of Dr Hudson’s resignation, current CFO Barbara Duncan has taken on the role and title of president and CFO, and current chief scientific officer Dr Phil Skolnick has been named executive vice president and CSO. Meanwhile, current Dov chairman Dr Arnold Lippa is now executive chairman of the board of directors.
“We arrived at these decisions and this new management structure in a collaborative way and with the best interests of our investors, employees and partners in mind,” said Dr Lippa.